BUY Aurobindo Pharma — Prakash Gaba
byPrakash GabaHorizon: NA (inferred Intraday)6 Aug 2026, 8:59 am ISTvia CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Aurobindo Pharma's Q1 Margin Story Improves; Macquarie Says Growth Picture Is Still Uneven
NewsNdtv-Profit·6 Aug · today
Aurobindo Pharma Q1 Results: Profit, EBITDA beat estimates on strong global demand
NewsCnbc-Tv18·5 Aug · today
Aurobindo Pharma Q1 Results: Profit Jumps 25%, Revenue Rises To Rs 9,150 Crore; Margins Improve
NewsNdtv-Profit·5 Aug · today
4 advisors have active swing BUY calls on this stock, all issued in the last 14 days
Advisor consensus · adjacent horizon·5 Aug · today
Aurobindo Pharma shares rise 2.01% in today's trade
NewsGoogle News·4 Aug · yesterday
Stock Picks Today: Cummins, Berger Paints, Aurobindo Pharma, Hindalco Novelis, Metropolis, And More On Brokerages' Radar
NewsNdtv-Profit·6 Aug · today
Aurobindo Pharma has announced its unaudited financial results for the first quarter ended June 30, 2026. The company has provided a press release detailing these results.
NSE · Press Release·5 Aug · today
Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
NSE · Outcome of Board Meeting·5 Aug · today
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.